| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chiara Rapinesi, Georgios D Kotzalidis, Lorenzo Mazzarini, Roberto Brugnoli, Stefano Ferracuti, Sergio De Filippis, Ilaria Cuomo, Gloria Giordano, Antonio Del Casale, Gloria Angeletti, Gabriele Sani, Paolo Girard. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review. Clinical drug investigation. vol 39. issue 8. 2019-10-28. PMID:31152368. |
long-acting injectable (lai) aripiprazole formulations in the treatment of schizophrenia and bipolar disorder: a systematic review. |
2019-10-28 |
2023-08-13 |
Not clear |
| Charles Nguyen, Andrei Novac, Jessica Hazen, Pamela Howard, Ryan Tieu, Robert G Bot. Weight gain changes in patients with aripiprazole monotherapy compared with aripiprazole-antidepressant polypharmacy in an outpatient sample. Journal of psychopharmacology (Oxford, England). vol 32. issue 4. 2019-10-11. PMID:29215304. |
this study seeks to evaluate the weight gain effect within a community-based population of patients with diagnoses of depression, mood disorder, and schizophrenia receiving aripiprazole over a period of at least 6 months. |
2019-10-11 |
2023-08-13 |
Not clear |
| Istvan Laszlovszky, Bela Kiss, Agota Barabassy, Margit Kapas, Gyorgy Nemet. [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 21. issue 3. 2019-10-02. PMID:31537751. |
cariprazine, which has received centralized market authorization from the european medicines agency in 2017 for the treatment of adult patients with schizophrenia (including those with predominant negative symptoms of schizophrenia) differs from the other two partial agonist antipsychotics aripiprazole and brexpiprazole due to its unique features. |
2019-10-02 |
2023-08-13 |
Not clear |
| Leslie Citrome, Robert Risinger, Andrew J Cutler, Yangchun Du, Jacqueline Zummo, Henry A Nasrallah, Bernard L Silverma. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. CNS spectrums. vol 23. issue 4. 2019-10-01. PMID:28625204. |
effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the positive and negative syndrome scale-supportive analyses from a phase 3 study. |
2019-10-01 |
2023-08-13 |
Not clear |
| Leslie Citrome, Robert Risinger, Andrew J Cutler, Yangchun Du, Jacqueline Zummo, Henry A Nasrallah, Bernard L Silverma. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. CNS spectrums. vol 23. issue 4. 2019-10-01. PMID:28625204. |
aripiprazole lauroxil (al) is a long-acting injectable atypical antipsychotic that was evaluated for the treatment of schizophrenia in a randomized, placebo-controlled, phase 3 study. |
2019-10-01 |
2023-08-13 |
Not clear |
| Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya, Michael S Brode. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. Advances in therapy. vol 35. issue 10. 2019-09-30. PMID:30206822. |
medication adherence and discontinuation of aripiprazole once-monthly 400 mg (aom 400) versus oral antipsychotics in patients with schizophrenia or bipolar i disorder: a real-world study using us claims data. |
2019-09-30 |
2023-08-13 |
Not clear |
| Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya, Michael S Brode. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. Advances in therapy. vol 35. issue 10. 2019-09-30. PMID:30206822. |
few studies have compared adherence between long-acting injectable antipsychotics, especially for newer agents like aripiprazole once-monthly 400 mg (aom 400; aripiprazole monohydrate) and oral antipsychotics, in patients with schizophrenia or bipolar i disorder (bd-i) in a real-world setting. |
2019-09-30 |
2023-08-13 |
Not clear |
| Daniel Schöttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U Correll, Klaus Wiedeman. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC psychiatry. vol 18. issue 1. 2019-09-13. PMID:30428862. |
effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. |
2019-09-13 |
2023-08-13 |
Not clear |
| Daniel Schöttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U Correll, Klaus Wiedeman. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC psychiatry. vol 18. issue 1. 2019-09-13. PMID:30428862. |
in this study, the treatment of schizophrenia patients with aripiprazole once-monthly (aom) was evaluated under real-life conditions in a naturalistic setting. |
2019-09-13 |
2023-08-13 |
Not clear |
| Itaru Miura, Yasuto Kunii, Mizuki Hino, Hiroshi Hoshino, Junya Matsumoto, Keiko Kanno-Nozaki, Sho Horikoshi, Haruka Kaneko, Miki Bundo, Kazuya Iwamoto, Hirooki Yab. DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study. Journal of psychiatric research. vol 100. 2019-06-28. PMID:29499474. |
dna methylation of ankk1 and response to aripiprazole in patients with acute schizophrenia: a preliminary study. |
2019-06-28 |
2023-08-13 |
human |
| Itaru Miura, Yasuto Kunii, Mizuki Hino, Hiroshi Hoshino, Junya Matsumoto, Keiko Kanno-Nozaki, Sho Horikoshi, Haruka Kaneko, Miki Bundo, Kazuya Iwamoto, Hirooki Yab. DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study. Journal of psychiatric research. vol 100. 2019-06-28. PMID:29499474. |
the objective of the present study was to investigate the effect of the dna methylation of ankk1 (ankyrin repeat and kinase domain containing 1) on the response to aripiprazole and plasma levels of monoamine metabolites in antipsychotic-free acute schizophrenia patients. |
2019-06-28 |
2023-08-13 |
human |
| Itaru Miura, Yasuto Kunii, Mizuki Hino, Hiroshi Hoshino, Junya Matsumoto, Keiko Kanno-Nozaki, Sho Horikoshi, Haruka Kaneko, Miki Bundo, Kazuya Iwamoto, Hirooki Yab. DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study. Journal of psychiatric research. vol 100. 2019-06-28. PMID:29499474. |
the subjects were 34 japanese patients with schizophrenia who had been treated with aripiprazole for 6 weeks. |
2019-06-28 |
2023-08-13 |
human |
| Robert Risinger, Marjie Hard, Peter J Weide. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Psychopharmacology bulletin. vol 47. issue 3. 2019-06-25. PMID:28839337. |
aripiprazole lauroxil (al) is an fda-approved treatment for schizophrenia. |
2019-06-25 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Ralph Aquila, Arielle D Stanford, Hasan H Jamal, Peter J Weiden, Robert Risinge. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil. Psychopharmacology bulletin. vol 47. issue 3. 2019-06-25. PMID:28839338. |
metabolic and endocrine profiles during 1-year treatment of outpatients with schizophrenia with aripiprazole lauroxil. |
2019-06-25 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Ralph Aquila, Arielle D Stanford, Hasan H Jamal, Peter J Weiden, Robert Risinge. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil. Psychopharmacology bulletin. vol 47. issue 3. 2019-06-25. PMID:28839338. |
we assessed long-term metabolic and endocrine profiles of outpatients with schizophrenia participating in a one-year open-label extension study of monthly aripiprazole lauroxil (al), a long-acting injectable antipsychotic. |
2019-06-25 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Ali Fathi, Sadhana Thiyanavadivel, Ofer Agid, Gary Remingto. Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials. The Journal of clinical psychiatry. vol 79. issue 2. 2019-06-25. PMID:29570965. |
can aripiprazole worsen psychosis in schizophrenia? |
2019-06-25 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Ali Fathi, Sadhana Thiyanavadivel, Ofer Agid, Gary Remingto. Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials. The Journal of clinical psychiatry. vol 79. issue 2. 2019-06-25. PMID:29570965. |
numerous case reports have reported psychotic worsening when switching to or adding aripiprazole in patients with schizophrenia. |
2019-06-25 |
2023-08-13 |
Not clear |
| Christoph U Correll, Arielle D Stanford, Amy Claxton, Yangchun Du, Peter J Weide. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Psychiatry research. vol 274. 2019-06-13. PMID:30802689. |
social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. |
2019-06-13 |
2023-08-13 |
Not clear |
| Chris Cameron, Jacqueline Zummo, Dharmik Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weide. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. Current medical research and opinion. vol 34. issue 4. 2019-06-11. PMID:29179595. |
efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. |
2019-06-11 |
2023-08-13 |
Not clear |
| Chris Cameron, Jacqueline Zummo, Dharmik Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weide. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. Current medical research and opinion. vol 34. issue 4. 2019-06-11. PMID:29179595. |
aripiprazole lauroxil (al) is a long-acting injectable atypical antipsychotic recently approved for the treatment of schizophrenia. |
2019-06-11 |
2023-08-13 |
Not clear |